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A B S T R A C T
Purpose: To determine the utility and tolerability of levetiracetam (LEV) compared to phenytoin (PHT) in
preventing clinical seizures in patients with subarachnoid hemorrhage (SAH).
Methods: Utility and tolerability of PHT and LEV in patients with SAH were determined by the
occurrence of breakthrough clinical seizures or adverse events necessitating a change of medication.
Comparisons were performed with Chi-square tests.
Results: All 176 patients were initially treated with PHT. No breakthrough clinical seizures occurred. In
70 (39.8%) patients, PHT was replaced with LEV due to adverse events including elevation of
transaminases, thrombocytopenia, unexplained fever, rash, gastrointestinal disturbance, and worsening
mental status. After switching to LEV, all adverse effects resolved except gastrointestinal disturbance
and worsening mental status in 4 patients. Adverse events occurred more often in patients taking PHT.
Conclusions: In patients with SAH, LEV appears to have superior tolerability compared to PHT.
Published by Elsevier Ltd on behalf of British Epilepsy Association.
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journal homepage: www.e lsev ier .com/ locate /yse izSubarachnoid hemorrhage (SAH) is a neurological emergency
with high mortality and morbidity. The incidence of SAH ranges
from 8 to 10.5 per 100,000 per year.1,2 Over the last few decades,
SAH mortality has decreased, mostly due to improvements in the
neurologic intensive care units (NICU). Despite this improved care,
themortality remains high, with asmany as 36% of patients dying.3
The markers for poor outcome are the patient’s level of
consciousness upon admission, age, amount of blood seen on
the initial computed tomography (CT) scan, cerebral vasospasm,
re-bleeding, surgical complications, and seizures.4–8
Seizures can occur at presentation of SAH or later in the disease
course. The re-bleeding rate and severe disability is higher in SAH
patients who have seizures. Seizures can also cause destabilization
of critically ill patients. The presence of seizures is recognized as an
independent predictor of poor outcome in patients with SAH.4 The
American Heart Association (AHA) guidelines suggest that
prophylactic antiepileptic drugs (AED) may be considered in the
immediate posthemorrhagic period.9
The use of PHT in critically ill patients is complicated by its
complex pharmacokinetics and adverse events. Levetiracetam
(LEV) is a chemically unrelated AED that has linear pharmacoki-
netics and is not hepatically metabolized. Its efﬁcacy has been
demonstrated in a wide variety of seizure types and status* Corresponding author at: 202 Bell Building, Box 3678, Duke University Medical
Center, Durham, NC 27710, United States. Tel.: +1 919 684 8485;
fax: +1 919 684 8955.
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doi:10.1016/j.seizure.2009.09.003epilepticus.10 In an intensive care unit or other inpatient setting,
therapy can be initiated at a therapeutic dose without risk of AED
hypersensitivity syndrome. These favorable properties of LEV
suggest that it may have a unique role in patients with SAH to
prevent seizures and minimize adverse events. The purpose of this
study was to determine the utility and tolerability of LEV in
patients with SAH, and see how it compares to PHT.
1. Methods
All patients admitted to Duke University Medical Center with
non-traumatic SAH between January 1, 2002 and June 30, 2006
were considered for enrollment in this study. Charts of patients
who were treated with either PHT or LEV were reviewed in detail.
This study was approved by the local Institutional Review Board
(IRB).
Chart review included review of admission history and physical
examination. Presence of clinical seizures was noted. Routine and
prolonged electroencephalograms (EEG) were also reviewed when
available to document frequency of seizures. Utility of the AEDwas
determined by noting whether breakthrough clinical seizures
occurred.
Adverse events andwhether the AEDwas switched due to these
adverse events were noted. In particular the adverse events
evaluated in detail included elevation of transaminase levels,
thrombocytopenia, unexplained fever, rash, andworseningmental
status. Any elevation of transaminase levels was identiﬁed, but
elevations that were twice the upper limit of normal were
speciﬁcally noted. Platelet count of less than 100,000 mm3 and aAssociation.
Table 2
Number of patients experiencing adverse events.
Side effect PHT
(n=176) (%)
LEV
(n=70) (%)
P value
Breakthrough clinical seizures 0 0 NS
Elevated transaminases 53a (30.1) 0 <0.001
Thrombocytopenia 21 (11.5) 0 <0.001
Unexplained fever 10 (5.7) 0 <0.05
Rash 3 (1.7) 0 NS
GI disturbance 4 (2.3) 1 (1.4) NS
Worsening mental status 9 (5.1) 3 (4.3) NS
a Of these only 23 (43.4%) patients were switched to LEV. PHT=phenytoin,
LEV= levetiracetam, NS=not signiﬁcant, and GI=gastrointestinal.
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or level of alertness was considered worsening mental status.
Complaints of nausea, vomiting, or diarrhea were noted as
gastrointestinal disturbance.
The AED dose and plasma concentration and renal function
tests results were also noted when available. Discharge summaries
and ﬁrst follow-up neurology or neurosurgery clinic evaluations
were reviewed to determine whether AED adverse events had
resolved. Only patients that had at least one follow-up visit were
included. The frequency withwhich the AED needed to be changed
and occurrence of adverse events were compared between the PHT
and LEV groups using Chi-square tests.
2. Results
A total of 176 patients, 113 women, with SAH were enrolled in
this study. The mean age of the patients was 58.2 (15.6) years. In
all patients the SAH was secondary to rupture of an intracranial
aneurysm. The site of the aneurysms is presented in Table 1.
Aneurysms of the anterior communicating artery were the most
common, occurring in 59 (33.5%) of patients. TheHunt andHess grade
was 3 or less in 111 (63%) patients, grade 4 in 51 (29%) patients, and
grade 5 in 14 (8%) patients. PHT and LEV were the only AED used in
this series of patients. All patients received PHT ﬁrst, and LEV was
used only if PHT resulted in adverse events. The PHT loading dosewas
20 mg/kg and maintenance dose was 5–7 mg/kg/day. The mean
plasma concentration of PHTwas 16 (6.1) mcg/mL. LEVwas starting
without a loading dose at 1500 mg twice a day. Plasma concentra-
tions for LEV were not available.
All patients were initially treated with PHT within 24 h of
symptom onset. Five (2.8%) patients had one or more clinical
seizures at presentation before administration of PHT. Clinical
seizures did not occur in any patient after initiation of AED therapy
until at least their ﬁrst follow-up. Either routine or prolonged EEG
was obtained in only 8 (4.5%) patients. Prolonged EEGswere 24 h in
length. Five of these EEGs were performed on patients who had
clinical seizures at presentation; these patients were on PHT. Two
additional patients being treated with PHT and one being treated
with LEV had an EEG because of worsening mental status. None of
the EEGs showed electrographic seizures or interictal epileptiform
activity.
Seventy (39.8%) of the PHT-treated patients were subsequently
switched to LEV. The switch occurred after a mean of 3.8 days after
start of treatmentwith PHT,with all patients having been switched
by day 10. Of these patients, 57 (81.4%) patients were switched
because of suspected PHT induced adverse events. These included
elevated transaminase levels, thrombocytopenia (platelet count of
less than 100,000 per mm3), unexplained fever (temperature
greater than 38 8C), and rash (Table 2). All patients with
thrombocytopenia, unexplained fever, and rash were switched
to LEV, however only 23 of the 53 (43.4%) patients with elevated
transaminase levels were switched. These 23 patients had
transaminase elevation greater than twice normal. Another 13
(18.6%) patients experienced gastrointestinal disturbance or
worsening mental status and were switched to LEV. TheTable 1
Aneurysms associated with diagnosis of SAH.
Location of aneurysm Number (%) of patients
Anterior communicating artery 59 (33.5)
Posterior communicating artery 33 (18.8)
Internal carotid artery 23 (13.1)
Middle cerebral artery 22 (12.5)
Basilar tip 15 (8.5)
All other 24 (13.6)association of these adverse events with PHT was considered
uncertain; however a change in AED occurred regardless.
While on LEV, none of the 70 patients had clinical seizures. All
56 patients who were switched to LEV because of elevated
transaminase levels, thrombocytopenia, unexplained fevers, or
rash had resolution of these adverse events by the time they were
discharged from the hospital or by the ﬁrst follow-up clinic visit
(14–41 days after discharge). The frequency of the ﬁrst three
adverse eventswas signiﬁcantly higher in the PHT group compared
to the LEV groups (Table 2). Of the 4 patients with gastrointestinal
disturbance prompting the change in AED to LEV, 3 (75%)
improved. Worsening mental status prompted a change in the
AED in 9 patients; 6 (66.7%) patients improved after being
switched to LEV. One patient continued to have GI disturbance and
3 continued to have worsenedmental status. It is possible that LEV
may have caused these adverse effects in 4 (5.7%) patients. All
patients continued to take PHT or LEV at least until ﬁrst follow-up.
3. Discussion
In this retrospective study, patients with non-traumatic SAH
did not have breakthrough clinical seizures after treatment with
PHT or LEV. However, patients treatedwith PHT hadmore frequent
adverse events consisting of elevated transaminase levels,
thrombocytopenia, and unexplained fevers. In 39.8% of patients,
PHT had to be discontinued because of adverse events; in these
patients LEV was used instead. Serious adverse events leading to
discontinuation of LEV were not seen.
Seizures are a complication of SAH. Variables that increase the
incidence of seizures after SAH include high grade, age less than 50
years, rupture of a middle cerebral artery aneurysm, intracerebral
hematoma, blood in the quadrigeminal cistern, persistent neuro-
logical deﬁcit, and re-bleeding.11 In older studies, seizures were
reported to occur in up to 26% of patients with aneurismal SAH.12
However, more recent studies noted that between 5 and 11% of
patients develop seizures around the time of the hemorrhage.5,13,14
The declining incidence of seizures has been attributed to
improved NICU care and the routine use of prophylactic AED. In
the present series, only 2.8% of patients had seizures. All these
occurred at onset of the SAH and prior to institution of AED
therapy. The relatively low incidence of seizures may be due to the
routine use of prophylactic AED.
Whether AED should be used prophylactically in all patients
presenting with SAH is debated. Since the incidence of seizures in
this patient population has diminished considerably in the last 20
years, some investigators have suggested that routine use of
prophylactic AED is not justiﬁed.14 However, others have
suggested that the incidence of nonconvulsive seizures detected
with continuous EEG monitoring is as high as 19% in patients with
SAH.15 Moreover, the prognosis is worse in patients who have
seizures.4,5,16,17 The Stroke Council of the American Heart
Association notes that seizures may result in neuronal injury
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treated aggressively.18 Moreover, they and others suggest that
prophylactic AED therapy with PHT should be considered.2,18 All
patients presenting to the NICU at Duke University Medical Center
with SAH are prophylactically treatedwith PHT initially. AED use is
typically continued for at least 6months. During the time period in
which this study was conducted, continuous EEG monitoring was
not routinely used to monitor SAH patients, thus potentially
underestimating the frequency of seizures.
Several recent studies have raised doubts about whether PHT is
the best AED to use for prevention of seizures in critically ill
patients with SAH. Higher PHT dose was found to result in worse
neurologic and cognitive outcomes in SAH survivors.19 PHT may
also interfere with the metabolism of nimodipine, which is
commonly used to minimize vasospasm. Nimodipine is metabo-
lized by the cytochrome P-450 isozyme of the hepatic microsomal
enzyme system. This system is induced by PHT, thus increasing the
metabolism of nimodipine.20 This may leave patients more
susceptible to vasospasm from lower nimodipine concentra-
tion.21,22 Since evaluation of vasospasm was not a focus of this
study, it is not certain whether patients treated with PHT in this
study had this complication more often. Unexplained fever may
occur with PHT, which may worsen prognosis.23 Finally, the use of
PHT in the NICU is challenging due to frequent adverse events, a
narrow therapeutic range, nonlinear pharmacokinetics, and
frequent monitoring of total and free levels, especially during
vasospasm.13,24
Many of the issues complicating the use of PHT in critically ill
patientswere noted in this study aswell. Elevation of transaminase
levels, thrombocytopenia, unexplained fevers, and rash occurred
commonly in patients treated with PHT. Though not a focus of the
study, it was noted that the dose of PHT was frequently changed to
maintain an appropriate plasma concentration. Nimodipine
plasma concentration was not available in this study, so whether
PHT resulted in increased clearance of this medication is unclear.
LEV is a novel AED whose exact mechanism of action is
unknown. Recent evidence shows that it binds to the synaptic
vesicle protein 2A (SV2A), which is involvedwith neurotransmitter
release from nerve cells.25,26 Additionally, LEV also has indirect
effects on gamma amino butyric acid (GABAergic) neurotransmis-
sion, modulates potassium and high voltage calcium currents, and
inﬂuences expression of genes associated with kindling.27 It has
linear pharmacokinetics with low intra- and inter-subject varia-
bility. The bioavailability of LEV is not affected by food, it not
protein-bound and does not affect the protein binding of other
drugs, and its volume of distribution is close to the volume of intra
and extra-cellular water.28,29 LEV has also been shown to be
neuroprotective in the animal models of SAH, closed head injury,
and self-sustaining status epilepticus.30,31 The efﬁcacy of LEV has
been demonstrated in partial and generalized seizures as well as
status epilepticus.10,32 Many of the patients in this study received
the oral formulation of LEV, which is difﬁcult to administer in
critically ill patients. In the last few years, intravenous LEV has
become available, and its administration has become much easier
and quicker in the NICU.
LEV has been used instead of PHT with favorable results in
critically ill patients.33–36 Patients with acute brain injury and after
supratentorial neurosurgery were noted to have problems similar
to those discussed above when treated with PHT.33,35 Switching
these patients to LEV resulted in fewer complications.
Themain limitation of this study is that it was retrospective and
relatively small in size with unequal groups. When comparing two
AED, a prospective, randomized trial would provide the most
robust data. Such a trial is difﬁcult to perform because of the
urgency of treatment of SAH patients and issues surrounding
informed consent in patients with worsening mental status. Aretrospective analysis, such as this one, provides preliminary data
suggesting the utility of LEV in this patient population and may
lead to further studies. Details of PHT and LEV serum levels were
not analyzed in this study. This was because the focus of the study
was whether PHT was discontinued or not, not how difﬁcult it was
to maintain consistent levels. This study also does not address the
incidence of seizures in SAH acutely and long term and whether
prophylactic AED therapy should be used in every patient. Drugs
other than PHT and LEV were also not evaluated. Though valproic
acid (VPA) has been reported to be useful in SAH, it was not used in
any patient in this series.21,22 How VPA would compare to LEV
cannot be answered by this study.
Seizures are a complication of SAH. PHT is used commonly to
prevent seizures in the acute phase of management. The
complicated pharmacokinetics, interactions with other commonly
used drugs, and adverse effects of PHT often necessitate changing
therapy. LEV appears to be well tolerated in patients with SAH, has
linear pharmacokinetics, no signiﬁcant drug–drug interactions,
lacks many of the side effects of PHT, and is available in an
intravenous formulation. It may be reasonable to consider LEV for
prophylactic treatment of seizures in patients presenting with
SAH.
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